Ulcerative Colitis [2016]: Bulletin #3
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world analyses for Entyvio (vedolizumab) in UC; InDex Pharmaceuticals announcing that it has enrolled the first patient in the Phase IIb CONDUCT trial for Kappaproct (cobitolimod); as well as Amgen announcing the European Commission approval of Amgevita (biosimilar adalimumab) in all available indications, including moderate-to-severe UC.
Business Questions
Business Questions
- How do KOLs regard real-world analyses of Entyvio?
- What potential threats could Entyvio face in the future?
- What are KOL views on Kappaproct and how would this agent be used if approved?
- What impact is Amgevita/Amjevita expected to have on the UC anti-TNF market?
- According to KOLs, which anti-TNF biosimilar is expected to have the most success in UC?
